Lentiviral In Vivo CD19 CAR T-Cell Therapy in Neurologic Autoimmune Disorders 2026 Cheng et al

[Jaybee00]

https://www.nejm.org/doi/full/10.10...=featured_secondary_home#core-collateral-info
Abstract
Among 16 patients with refractory neurologic autoimmune disorders, lentiviral CD19 CAR T-cell therapy was associated with manageable side effects, complete B-cell depletion, and preliminary clinical improvement across disease groups. Paywalled.

https://www.nejm.org/doi/full/10.1056/NEJMc2603114

 

[Jaybee00]

“B-cell depletion, rebooting the immune system, is emerging as potentially curative for some refractory autoimmune diseases.
But that has mainly relied on complicated, time-consuming, laborious ex vivo (outside the body) methods.
Today @NEJM all 16 patients with refractory autoimmune neurologic conditions, including 7 with progressive multiple sclerosis, had clinical and biologic improvement with single dose in vivo (inside the body, off-the shelf lentivirus vector) B cell depletion.”

Hard to see the clinical outcome measures.

 

[Jonathan Edwards]

B-cell depletion, rebooting the immune system, is emerging as potentially curative for some refractory autoimmune diseases.

It has been 'emerging' for nearly 30 years now, ducky, if you read the literature.

 

[Jaybee00]

Quantitative Myasthenia Gravis (QMG) score decreased substantially.

 

[Jaybee00]

A video shows a patient with progressive multiple sclerosis attempting to walk before and after treatment with JY231, an off-the-shelf lentiviral vector designed for the direct in vivo engineering of CD19-targeted CAR T cells. Learn more in the preliminary results of a phase 1 trial: nej.md/4zPPwbD